Promising role of polymeric nanoparticles in the treatment of rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory illness caused by an autoimmune
disorder of synovial membrane resulting in synovial membrane dysfunction. The available …
disorder of synovial membrane resulting in synovial membrane dysfunction. The available …
Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries
HK Yoo, HG Byun, F Caprioli, M Fumery… - BMC Health Services …, 2022 - Springer
Abstract Background In 2020, the European Medicines Agency approved infliximab
subcutaneous (SC) for the treatment of inflammatory bowel disease. This new mode of …
subcutaneous (SC) for the treatment of inflammatory bowel disease. This new mode of …
[HTML][HTML] Adherencia al tratamiento en artritis reumatoide: condición indispensable para el control de la enfermedad
C Ruiz Mejía, AM Parada Pérez… - Revista Cubana de …, 2016 - scielo.sld.cu
Introducción: la artritis reumatoide es la poliartritis inflamatoria más frecuente en el adulto y
generalmente lleva a discapacidad funcional, lo cual impacta de manera dramática en la …
generalmente lleva a discapacidad funcional, lo cual impacta de manera dramática en la …
Etanercept (Enbrel®) alternative storage at ambient temperature
E Shannon, J Daffy, H Jones, A Paulson… - Clinical Pharmacology …, 2017 - Taylor & Francis
Background Biologic disease-modifying antirheumatic drugs, including tumor necrosis factor
inhibitors such as etanercept (Enbrel®), have improved outcomes for patients with rheumatic …
inhibitors such as etanercept (Enbrel®), have improved outcomes for patients with rheumatic …
Culturally sensitive care of Misak Indigenous patients with rheumatoid arthritis in Columbia
A Ospina-Caicedo, E Castro Franco… - Rural and Remote …, 2022 - search.informit.org
Introduction: To describe and understand the attitudes, cultural knowledge, and therapeutic
practices of the Misak people concerning rheumatoid arthritis (RA), inscribed in an emergent …
practices of the Misak people concerning rheumatoid arthritis (RA), inscribed in an emergent …
Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic/pharmacodynamic simulations
C Bastida, ADR Huitema, MJ l'Ami… - European journal of …, 2020 - Springer
Purpose Tocilizumab is a humanized monoclonal antibody approved for rheumatoid arthritis
treatment. In clinical practice, empirical dose-tapering strategies are implemented in patients …
treatment. In clinical practice, empirical dose-tapering strategies are implemented in patients …
Cost-minimization analysis of biologic disease-modifying antirheumatic drugs administered by subcutaneous injections in patients with rheumatoid arthritis
SH Park, MY Lee, EK Lee - Korean Journal of Clinical Pharmacy, 2016 - koreascience.kr
Background: The subcutaneous formulation of biologic disease-modifying antirheumatic
drugs (DMARDs) was preferred due to favored self-administration and would be an …
drugs (DMARDs) was preferred due to favored self-administration and would be an …
Budget Impact Analysis of the Subcutaneous Infliximab (CT-P13 SC) for Treating Inflammatory Bowel Disease in the EU-5 Countries
HK Yoo, HG Byun, F Caprioli, M Fumery… - 2022 - researchsquare.com
Background: In 2020, the European Medicines Agency approved CT-P13 subcutaneous
(SC) for the treatment of inflammatory bowel disease. This new mode of infliximab …
(SC) for the treatment of inflammatory bowel disease. This new mode of infliximab …
Monitorización de Infliximab en patologías inflamatorias
L Rentero Redondo - dspace.umh.es
Objetivo Determinar la concentración media de Infliximab (INF) según las diferentes
patologías de uso y determinar la prevalencia de pacientes en rango terapéutico tras una …
patologías de uso y determinar la prevalencia de pacientes en rango terapéutico tras una …
피하주사로투여하는생물학적항류마티스제제의비용최소화연구
박승후， 이의경， 이민영 - 한국임상약학회지, 2016 - dbpia.co.kr
Background: The subcutaneous formulation of biologic disease-modifying antirheumatic
drugs (DMARDs) was preferred due to favored self-administration and would be an …
drugs (DMARDs) was preferred due to favored self-administration and would be an …